Prudential Financial Inc Apellis Pharmaceuticals, Inc. Transaction History

Prudential Financial Inc

  • $70.8 Billion
  • Q4 2024

A detailed history of Prudential Financial Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Prudential Financial Inc holds 198,060 shares of APLS stock, worth $5.43 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
198,060
Previous 287,760 31.17%
Holding current value
$5.43 Million
Previous $8.3 Million 23.84%
% of portfolio
0.01%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
SELL
$26.18 - $35.42 $2.35 Million - $3.18 Million
-89,700 Reduced 31.17%
198,060 $6.32 Million
Q3 2024

Nov 13, 2024
BUY
$28.84 - $41.15 $1.23 Million - $1.75 Million
42,500 Added 17.33%
287,760 $8.3 Million
Q2 2024

Aug 13, 2024
SELL
$38.07 - $59.71 $11,421 - $17,913
-300 Reduced 0.12%
245,260 $9.41 Million
Q1 2024

May 14, 2024
SELL
$55.39 - $72.47 $4.49 Million - $5.87 Million
-81,000 Reduced 24.8%
245,560 $14.4 Million
Q4 2023

Feb 13, 2024
BUY
$37.14 - $64.82 $854,220 - $1.49 Million
23,000 Added 7.58%
326,560 $19.5 Million
Q3 2023

Nov 13, 2023
BUY
$23.65 - $89.22 $2.99 Million - $11.3 Million
126,480 Added 71.43%
303,560 $11.5 Million
Q2 2023

Aug 11, 2023
SELL
$76.68 - $93.31 $19,860 - $24,167
-259 Reduced 0.15%
177,080 $16.1 Million
Q1 2023

May 12, 2023
SELL
$46.59 - $66.96 $1,956 - $2,812
-42 Reduced 0.02%
177,339 $11.7 Million
Q4 2022

Feb 14, 2023
SELL
$43.24 - $61.04 $172,657 - $243,732
-3,993 Reduced 2.2%
177,381 $0
Q3 2022

Nov 04, 2022
BUY
$44.76 - $69.66 $615,181 - $957,407
13,744 Added 8.2%
181,374 $12.4 Million
Q2 2022

Aug 15, 2022
SELL
$35.07 - $59.21 $5.77 Million - $9.74 Million
-164,572 Reduced 49.54%
167,630 $7.58 Million
Q1 2022

May 13, 2022
BUY
$35.46 - $54.12 $5.39 Million - $8.22 Million
151,932 Added 84.28%
332,202 $16.9 Million
Q4 2021

Feb 14, 2022
BUY
$30.74 - $49.16 $272,817 - $436,294
8,875 Added 5.18%
180,270 $8.74 Million
Q3 2021

Nov 15, 2021
SELL
$31.4 - $69.84 $400,193 - $890,110
-12,745 Reduced 6.92%
171,395 $5.65 Million
Q2 2021

Aug 16, 2021
BUY
$40.9 - $64.9 $784,462 - $1.24 Million
19,180 Added 11.63%
184,140 $11.6 Million
Q1 2021

May 12, 2021
BUY
$40.8 - $57.39 $8,159 - $11,478
200 Added 0.12%
164,960 $7.08 Million
Q4 2020

Feb 16, 2021
BUY
$30.79 - $57.2 $1.25 Million - $2.32 Million
40,490 Added 32.58%
164,760 $9.43 Million
Q3 2020

Nov 16, 2020
BUY
$25.89 - $33.65 $906,564 - $1.18 Million
35,016 Added 39.23%
124,270 $3.75 Million
Q2 2020

Aug 12, 2020
BUY
$24.8 - $38.49 $19,641 - $30,484
792 Added 0.9%
89,254 $2.92 Million
Q1 2020

May 12, 2020
BUY
$17.91 - $44.33 $285,951 - $707,772
15,966 Added 22.02%
88,462 $2.37 Million
Q4 2019

Feb 11, 2020
SELL
$22.1 - $30.8 $781,544 - $1.09 Million
-35,364 Reduced 32.79%
72,496 $2.22 Million
Q3 2019

Nov 13, 2019
SELL
$24.09 - $32.18 $655,729 - $875,939
-27,220 Reduced 20.15%
107,860 $2.6 Million
Q2 2019

Aug 08, 2019
SELL
$18.0 - $25.34 $429,480 - $604,612
-23,860 Reduced 15.01%
135,080 $0
Q1 2019

May 15, 2019
SELL
$12.81 - $19.82 $823,939 - $1.27 Million
-64,320 Reduced 28.81%
158,940 $0
Q4 2018

Feb 07, 2019
BUY
$11.47 - $18.71 $448,821 - $732,122
39,130 Added 21.25%
223,260 $2.94 Million
Q3 2018

Nov 07, 2018
BUY
$16.57 - $21.03 $815,741 - $1.04 Million
49,230 Added 36.49%
184,130 $0
Q2 2018

Aug 13, 2018
BUY
$19.63 - $30.0 $2.65 Million - $4.05 Million
134,900 New
134,900 $0

Others Institutions Holding APLS

# of Institutions
304
Shares Held
117M
Call Options Held
3.03M
Put Options Held
1.05M
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.01B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email